A site where you can find recommended contractors for non-clinical testing｜effical " List of Drug Discovery Modalities " mRNA

mRNA

mRNA" is an abbreviation for messenger RNA.

What is mRNA?Nucleic acid medicine for temporary expression of a target protein in the bodyThe goal is therapeutic effect by producing necessary proteins within cells. While widely known for its application in infectious disease vaccines, it is also expected to be utilized in a wide range of fields in recent years, such as protein replacement therapy and cancer immunotherapy. Advances in delivery technologies, including lipid nanoparticles (LNPs), have made it possible to efficiently deliver mRNA to target cells, and the practical application of various mRNA drugs is progressing.

Representative example of mRNA

Comirnaty (BNT162b2)

Comirnaty (BNT162b2) is,COVID-19 mRNA vaccines that deliver mRNA into the body using lipid nanoparticles (LNPs)This is a prime example that has greatly advanced the practical application of mRNA therapeutics in the field of infectious diseases, and the research and development of mRNA therapeutics for various diseases is accelerating globally based on this practical application.

Spikevax (mRNA-1273)

Spikevax (mRNA-1273) isCOVID-19 mRNA vaccine combining LNP (lipid nanoparticles) and mRNAThis is an example of a practical application of the mRNA platform, and it became an important achievement that broadened the possibilities of mRNA medicine applications not only for infectious disease prevention but also for various diseases.

Personalized cancer vaccine (under development)

Personalized cancer vaccines areTherapeutic method using mRNA encoding patient-specific cancer neoantigensIt is being developed. It is currently a prime example of a clinical trial and development stage, and as an approach that aims for personalized treatment for each patient, it is expected to be a promising technology that shows the future direction of mRNA drug discovery.

Key challenges in mRNA development

Delivery technologies for efficient delivery to target organizations

mRNA is difficult to be incorporated into cells on its own and is easily degraded in the body.Therefore,Delivery technology greatly impacts drug efficacy.LNP (lipid nanoparticle) and other DDS (drug delivery systems) are crucial foundational technologies for mRNA drug development, as they efficiently deliver mRNA to target tissues while protecting it.

Maintain adequate protein expression

In mRNA therapeutics,Ensure sufficient expression efficiency and durationThis directly leads to drug efficacy. Therefore, in addition to optimizing mRNA stability and translation efficiency, important development challenges include exploring biomarkers that consider patient variability and evaluating protein expression in vivo.

How to evaluate immunostimulation and human translatability

In mRNA therapeutics,Appropriately evaluate cytokine induction and inflammatory responses due to innate immune activationThis is required. In safety evaluations, it is expected that immune responses will be predicted using pathological models with high human extrapolation, allowing for a more accurate assessment of safety and efficacy from the preclinical stage to clinical trials.

Preclinical evaluation for mRNA development

Evaluate delivery to the target organization

Delivery assessment to the target organization isTo confirm if mRNA and LNPs are properly delivered to the target tissue.It is performed to understand the overall efficiency of delivery and pharmacokinetics by combining PK and LNP evaluations, in addition to in vivo distribution within the organization and distribution of nucleic acid drugs, and to evaluate their relationship with efficacy.

Multifaceted evaluation of protein expression and efficacy

In protein expression and efficacy evaluation,Comprehensively confirming target engagement, protein expression levels, and duration of expression.We will further evaluate the effectiveness more appropriately by combining biomarker analysis and pharmacological studies to assess the relationship between target action and efficacy from multiple perspectives.

Utilize disease models with high human translatability.

In disease models with high human translatability,Evaluate using a combination of organoids, iPS cells, humanized mice, and patient-derived models.We will leverage the characteristics of each model to predict drug efficacy and safety in humans more realistically, thereby improving the reliability of non-clinical evaluations.

Assessing the safety of mRNA therapeutics

In mRNA therapeutics,Comprehensive evaluation of specific safety, including immunostimulation and LNP-derived toxicity.We will also confirm long-term safety in addition to the presence or absence of cytokine storms and hepatotoxicity, and by combining multiple safety tests, we will gain a multifaceted understanding of the risks and enhance their translatability to clinical practice.

Key points when choosing a contract research organization (CRO) for non-clinical studies

mRNA is a drug discovery modality that holds promise for treating a wide range of diseases, including infectious diseases, cancer, and rare diseases, in addition to vaccines. However, challenges such as delivery, safety, and human extrapolation remain, making appropriate non-clinical evaluation essential. To advance development efficiently, selecting a CRO that understands the characteristics of mRNA therapeutics and can propose an evaluation strategy is key to success.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us